Efficacy study of a food supplement based on arabinoxylans obtained from barley on the reduction of postprandial glycemic response in healthy subjects: a monocentric, randomized, cross-over, double-blind, placebo-controlled clinical trial

HEALLO s.r.l.0 个研究点目标入组 40 人开始时间: 2022年3月22日最近更新: 2022年10月31日

试验速览

2022 Results article in https://doi.org/10.3390/nu14193916 (added 18/10/2022)

•1. Healthy subjects, according to what was determined by the clinical history and by the information provided during the recruitment
•2. Aged between 18 and 65 years
•3. Non-smokers
•4. Subjects able to understand and to sign the Informed Consent

•1. Subjects with type 1 or 2 diabetes
•2. Subjects with fasting blood glucose >110 mg/dl
•3. Subjects with blood pressure values >160/100 mmHg
•4. Subjects with metabolic disorders
•5. Subjects with endocrine, cardiovascular, pulmonary, renal or gastrointestinal diseases, which may interfere with the results of the study
•6. Subjects with sensitivity, intolerance or allergy to products used in the clinical trial
•7. Pregnant or lactating women
•8. Subjects who have donated blood in the 3 months prior to recruitment
•9. Subjects under pharmacological treatment, with drugs that could interfere with the study, such as alpha-glucosidase inhibitors (acarbose etc), insulin-sensitive drugs (metformin etc), sulfanilureee, cholesterol medications, and any other medications that the physician does not deem compatible with the study
•10.Subjects who were taking food supplements that could interfere with the study, such as products high in vitamins and minerals (>200% VNR), B vitamins, C vitamin, calcium, zinc, copper, chromium, iodine, iron, magnesium, manganese, phosphorus, essential fatty acid products, botanicals, and any other products that the physician does not deem compatible with the study.

发起方

HEALLO s.r.l.